Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Connor Johnson

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Blood|July 15, 2025
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell TherapyLeon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Blood Advances|January 24, 2022
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort studyJ Erika Haydu, Jenny S Maron, Robert A Redd, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Blood|July 15, 2025
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell TherapyLeon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, et al.
Blood Advances|October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell LymphomaJ Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Blood Advances|February 10, 2025
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphomaMatthew J Frigault, Ning Yao, Trisha R Berger, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Blood Advances|January 24, 2022
Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort studyJ Erika Haydu, Jenny S Maron, Robert A Redd, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2024
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma SubtypesBimarzhan Assatova, Robert Willim, Christopher Trevisani, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 6